David J. Mazzo was appointed as Caladrius' Chief Executive Officer and as a member of our Board on January 5, 2015. In addition, Dr. Mazzo was appointed as President of the Company in March 2017. Dr. Mazzo brings to the Company over 30 years of experience in the pharmaceutical industry. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a NASDAQ-listed biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc., a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulene SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also previously served on the Board of Avanir Pharmaceuticals, Inc., a biotechnology company which was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of pSivida Corp., a publicly held biopharmaceutical company, in the role of non-executive chairman.

Dr. Mazzo earned a BA in the Honors Program (interdisciplinary humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo received his MS in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Joseph Talamo was promoted to Senior Vice President and Chief Financial Officer in October 2015 from his previous role when he joined Caladrius in 2011 as the Corporate Controller and Chief Accounting Officer. He is a versatile finance executive with leadership experience in publicly-traded development and commercial-stage companies, along with a strong background in SEC compliance. He has led companywide forecasting, planning and analysis activities, including for M&A, and has had extensive experience with integrating transactions and raising capital. At Caladrius, Mr. Talamo has been responsible for numerous financial functions including SEC reporting, forecasting, planning and analysis, cash management and accounting.

Prior to joining Caladrius, from 1996 to 2010, Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. (“OSI”), a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo has served as Treasurer of the Stem For Life Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise, since 2012. Mr. Talamo also served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010.

Mr. Talamo received a BBA in accounting from Hofstra University in 1991, and an MBA in finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.

Dr. Losordo was appointed Chief Medical Officer of the Company effective August 5, 2013. Dr. Losordo served from 2006 to 2013 as a member of the Scientific Advisory Board of Caladrius. Prior to his appointment as the Company’s Chief Medical Officer, Dr. Losordo served as Vice President, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International from October 2011 through February 2013. He is an adjunct professor of medicine at Northwestern University in Chicago, Illinois. From 2006 through 2011, Dr. Losordo was the director of the Feinberg Cardiovascular Research Institute and the Eileen M. Foell Professor of Heart Research at Northwestern University’s School of Medicine and director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. From 2004 through 2006, he was a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth’s Medical Center in Boston. He is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. Dr. Losordo’s major research interests encompass angiogenesis/vasculogenesis, progenitor/adult stem cells, tissue repair/regeneration, and vascular biology. He received his M.D. from the University of Vermont.

Dr. Losordo has engaged in career-long efforts to develop novel therapeutics and as a scientist he obtained over $35 million in National Institutes of Health funding, for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals. Since 2012, he has served on the Scientific Advisory Board of The Stem For Life Foundation, a public charity devoted to accelerating development of cell therapies.

Todd Girolamo joined Caladrius in 2011. He is a seasoned attorney specializing in health-related products and businesses. As a member of the Caladrius senior management team, Mr. Girolamo has been responsible for managing all legal aspects of the Company’s research and development pipeline, from preclinical research to multinational pivotal clinical trials, including academic and corporate collaborations. He has been responsible for the Company’s licensing activities; the strategy, maintenance and prosecution of the Company’s extensive global patent estate; and the management of all litigation involving the Company and its subsidiaries.

Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel, and he concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Company and Summer Street Research Partners.

Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.

M.S. (computer science/computer forensics) Fairleigh Dickinson University

Greg Berkin joined Caladrius in January 2015. Since that time, Greg has been responsible for transforming external IT support into an internal team working as a highly efficient operating unit across all five Caladrius and PCT sites. He also manages all groups within IT: Networking, PC, Applications, Business Solutions, and Telecom.

Before joining Caladrius, Greg held director and management roles in IT at companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.

Greg has more than 20 years in the technical profession with 15 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, and cybersecurity.

John Menditto joined Caladrius Biosciences in 2017. He is an experienced corporate communications and investor relations professional. John’s stakeholder communications work is done in partnership with our Finance, Clinical, Regulatory, Legal, Human Resource and Executive teams. He reports directly to both the Chief Executive Officer and the Chief Financial Officer.

Mr. Menditto came to Caladrius with over 20 years of experience and specialization, particularly, in the areas of financial modeling, Regulation FD, corporate governance, investor targeting and capital raising. He has held senior roles at several healthcare and life science companies including Novartis Corporation, Medco Health Solutions and Argos Therapeutics. John has also spent a number of years as a senior communications consultant with The Imagination Group, Makovsky & Co. and MWWPR.

John is a former IR Magazine and PRSA/Big Apple award winner for his work in investor and corporate communications. He holds degrees in public relations and finance from Susquehanna University in Selinsgrove, Pennsylvania.